BetterLife Pharma Highlights BETR-001 Advantages Over LSD for Neurological Treatment

BetterLife Pharma Inc. highlighted the advantages of its proprietary compound BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide, following recent Phase 2 trial results showing LSD microdosing is ineffective for depression. The company emphasized that BETR-001 remains non-hallucinogenic even at high doses and does not induce tolerance with repeated use, allowing for chronic administration while maintaining effectiveness. This contrasts with psychedelic treatments that require specialized clinical settings and lengthy monitoring periods.

Dr. Ahmad Doroudian, CEO of BetterLife, stated that the ability to administer full doses without hallucinations overcomes significant treatment barriers associated with traditional psychedelic therapies. The company is completing IND-enabling studies and plans to file an Investigational New Drug application and begin human clinical trials by the second half of 2026. Initial development focuses on treating traumatic brain injury, cluster headaches, and migraine, with potential applications for various psychiatric disorders to be explored as development progresses.

BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles, and its pending composition and method of use patent covers treatment of neurological disorders until approximately 2042. The compound's non-controlled status allows for potential self-administration, distinguishing it from regulated psychedelic substances. For additional information about the company's developments, visit https://www.blifepharma.com.

The announcement comes as the field of neuroplastogen research expands, with companies seeking alternatives to traditional psychedelics that carry hallucinogenic effects and regulatory restrictions. BetterLife's approach addresses both clinical and practical challenges in neurological treatment development, potentially offering a more accessible therapeutic option. The company's progress will be closely watched as it moves toward clinical trials and further defines BETR-001's therapeutic profile across multiple neurological conditions.